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Penicillium marneﬀei is a dimorphic fungus which is endemic in Southeast Asia. It is an opportunistic pathogen which has
emerged to become an AIDS-deﬁning illness in the endemic areas. Early diagnosis with prompt initiation of treatment is crucial
for its management. Prompt diagnosis can often be established through careful cytological and histological examination of
clinical specimens although microbiological culture remains the gold standard for its diagnosis. Standard antifungal treatment
for AIDS patients with penicilliosis is well established. Highly active antiretroviral therapy should be started early together with
the antifungal treatment. Special attention should be paid to potential drug interaction between antiretroviral and antifungal
treatments. Secondary prophylaxis may be discontinued with a low risk of relapse of the infection once the immune dysfunction
has improved.
1.Introduction
Penicillium marneﬀei was ﬁrst discovered in 1959 by G.
Segretain at the Pasteur Institute in Paris. The strain was
isolated from bamboo rats dying of disseminated mycosis
in Vietnam. The new species was named P. marneﬀei in
honour of Hubert Marneﬀe, the Director of Pasteur Institute
in Indochina [1, 2]. The ﬁrst report of human infection
due to P. marneﬀei was also reported by G. Segretain who
accidentally pricked his ﬁnger with a needle containing
the yeast cells of P. marneﬀei. A small nodule appeared at
the site of infection followed by lymphangitis 9 days after
the accident [3]. The ﬁrst natural human infection was
reported in 1973 from a patient with Hodgkin lymphoma
who lived in Southeast Asia [4]. Before the ﬁrst case was
reported in 1988 in a patient infected with the human
immunodeﬁciency virus (HIV) [5], human penicilliosis
w a su n c o m m o nw i t hl e s st h a n4 0c a s e sr e p o r t e di nt h e
Southeast Asia [6, 7]. However, the incidence of penicilliosis
increased rapidly thereafter with the development of HIV
pandemic and the infection became one of the common-
est acquired immune deﬁciency syndrome (AIDS)-deﬁning
illnesses among HIV-positive patients in endemic areas [8–
10].
2.Mycology
P. marneﬀei is the only dimorphic fungus in the genus of
Penicillium. It exists in mycelial form at 25◦Cb u ty e a s tf o r m
at 37◦C[ 1]. It shows a rapid growth rate and matures within
3 days at 25–30◦C. Its growth is enhanced in Sabouraud
dextrose agar but is inhibited by cycloheximide [11]. At
25◦C, the colonies of P. marneﬀei are granular with shade
of greenish-yellow colour and a characteristic red diﬀusible
pigment (Figure 1). Little or no red diﬀusible pigment is
produced at 35 to 37◦C( Figure 2). Microscopically, the
mold form is typical of other Penicillium species with
hyaline septated hyphae and fruiting structures composing
of branching metulae and phialides which produce spherical
conidia in chains (Figure 3).
3. Epidemiology
3.1. Endemicity. P. marneﬀei infection is endemic among
HIV-positive patients in many areas in Southeast Asia,
including Thailand, Vietnam, Hong Kong, Southern China,
Taiwan, India, and Laos [6, 8, 9, 12–20]. So far, all reported
cases of P. marneﬀei infections in AIDS patients have showed2 Pathology Research International
Figure 1: Granular colony of P. marneﬀei with a characteristic
red diﬀusible pigment on Sabouraud’s dextrose agar after 7 days
incubation at 25◦C.
Figure 2: Yeast-like colony of P. marneﬀei without red diﬀusible
pigment on Sabouranud’s dextrose agar after 7 days of incubation
at 35◦C.
epidemiological link with the endemic areas except for one
case reported in an African from Ghana who had never
been to Southeast Asia [21]. Among the endemic areas, the
greatest number of cases was reported in Northern Thailand,
where penicilliosis is the third commonest AIDS-indicating
disease among HIV-positive patients [8, 22, 23].
3.2. Natural Reservoir and Mode of Transmission. Al o ti s
still unknown about the natural reservoir and route of
transmission of P. marneﬀei. Human and bamboo rats are
the only known animal hosts of P. marneﬀei.F o u rs p e c i e s
of bamboo rats, Rhizomys sinensis, Rhizomys pruinosus,
Rhizomys sumatrensis and Cannomys badius, are known to
be enzootic reservoirs. The distribution of these bamboo rat
species generally follows the distribution of endemicity of P.
marneﬀei [6, 24–28].
Figure 3: Microscopy of the mold form of P. marneﬀei showing
septated hyaline hypae and fruiting structures composing of
branching metulae and philiades with spherical condidia in chains
(lactophenol cotton blue ×400).
It is not certain whether human infection is a result
of exposure to infected animals or both bamboo rats and
human get infected because of exposure to a common
environmental source. The available information seems to
suggest the latter. A case-control study in Northern Thailand
comparing 80 cases of penicilliosis in patients with AIDS
and 160 control patients with AIDS but without penicilliosis
showed that exposure or consumption of bamboo rats was
notariskfactorforP. marneﬀeiinfection.Ontheotherhand,
a recent history of occupational or other exposure to soil
especially during rainy season was found to be a risk factor
[29]. An airborne route of transmission through inhalation
of conidia from an environmental source with subsequent
dissemination to other body sites during immunosuppres-
sion has been postulated [13, 30, 31]. However, soil samples
obtained from bamboo rat burrows and residential area of
patients withpenicilliosis wererarelypositive forP. marneﬀei
[25].
Penicilliosis was reported as a cause of laboratory-
associated infection. As demonstrated by G. Segretain,
localized infection was possible through direct inoculation
of the fungus into the skin [1]. Another laboratory-acquired
infection was reported in an undiagnosed HIV-positive
physician who visited a laboratory where students were
handling P. marneﬀei cultures on the open bench. He
developed disseminated infection shortly after the exposure
and the presumptive route of acquisition was inhalation
[32]. The CDC has recommended Biosafety Level-2 (BSL-
2) practices with containment equipment and facilities for
propagating and manipulating P. marneﬀei cultures [33].
3.3. Incubation Period. The incubation period of P. marneﬀei
infection has not been well deﬁned. A report of a patient
who lived in an nonendemic area but developed penicilliosisPathology Research International 3
11 years after visiting Hong Kong has suggested the possi-
bility of a long latency with subsequent reactivation [34].
There is also evidence that primary infection might occur
as P. marneﬀei infection can present early in young children
who had acquired HIV perinatally [35].
3.4. Seasonality. As e a s o n a lp a t t e r no fP. marneﬀei infection
has been observed in Northern Thailand with increased
incidence during the rainy seasons [29, 36]. As there should
not be any seasonal variation in the degree of immunosup-
pression in HIV, the marked seasonality suggests that many
of the infections are primary infection and that the heavy
rainfall provides a favorable condition for the growth of the
fungus, thus increasing the chance of exposure to susceptible
host [36].
4.Pathology
The pathology of penicilliosis in diﬀerent organs varies
depending on the host immunity. Anergic and necrotiz-
ing tissue reaction are often observed in AIDS patients.
Granuloma formation will help localize the infection and
prevent further dissemination. Failure of this response in
AIDS patients may explain the higher rate of disseminated
disease [7–9, 13, 37].
Themostfrequentsitesofinvolvementareliverandlungs
but lymph node, bone marrow, skin and intestines are also
aﬀected. In the liver, histiocyte inﬁltration of the sinusoids
and parenchyma is seen, and epithelioid granuloma may be
found. Of interest, no correlation of the liver function test
results with the histological changes has been observed [38].
In the lymph node, there is often lymphoid depletion with
histiocytic proliferation and focal necrosis [39]. In the bone
marrow,histiocytic proliferationcanbe prominent or subtle,
with or without granuloma formation. Rarely, a histiocytic
response is lacking [40]. Haemophagocytic syndrome has
also been reported [41].
5.ClinicalFeature
Penicilliosis is mostly seen in late HIV infection with CD4+
count less than 100/uL. Up to 80% or more of the cases have
CD4+ count below 50/uL [8, 18, 42]. Table 1 summarizes
the clinical features at presentation [8, 17, 18]. Most patients
have constitutional symptoms with fever, weight loss and
malaise. Skin manifestation such as subcutaneous abscesses
and papule-like ulcers may be present [43]. Molluscum-
contagiosum-like lesion is not infrequent (Figure 4). It is
common to have signs and symptoms reﬂecting involve-
ment of reticuloendothelial system including anaemia, hep-
atosplenomegaly and lympadenopathy. Respiratory involve-
ment is often present, with productive cough, dyspnoea and
haemoptyisis. Chest X-ray may show diﬀuse reticular inﬁl-
tration (Figure 5), localized alveolar inﬁltrates or cavitary
lesion [44]. Diarrhoea is not uncommon and sometimes
may be bloody. The infection may rarely present as acute
abdomen [45, 46]. Other presenting symptoms include
osteoarthritis, genital ulcers and oral lesions [16, 47–51].
Table 1: Symptomatology of penicilliosis in HIV-positive patients.
Study location (number of subjects)
Signs/symptoms Thailand [8] India [17] Hong Kong [18]
(N = 80) (N = 36) (N = 47)∗
Fever 93% 97% 96%
Skin lesion 71% 81% 28%
Anaemia 78% 86% 79%
Hepatomegaly 51% 39% 28%
Splenomegaly 16% 15%
Lymphadenopathy 58% 33% 62%
Diarrhoea 31% 22% 15%
Cough 49% — 40%
Presence of other OIs 55% 77% 57%
OI: opportunistic infection.
∗94% of the 47 subjects are conﬁrmed HIV positive.
Figure4:Molluscum-contagiosum-likeskinlesionsassociatedwith
P. marneﬀei infection.
Central nervous system involvement is uncommon. A
groupfromVietnamhas,however,reportedthedevelopment
of a syndrome of acute altered mental status with confusion,
agitation, or depressed consciousness in the setting of sub-
acute febrile illness [50]. Examination of the cerebrospinal
ﬂuid (CSF) could be normal, and abnormal cell count was
seen only in one third of the cases. 71% had elevated CSF
proteinand24%caseshadaCSFglucose/serumglucoseratio
<0.5. The disease course was rapidly progressive with a high
mortality.
Since penicilliosis is usually seen in advanced stage of
HIV infection, 55 to 77% of cases may have other concurrent
opportunistic infections such as tuberculosis, disseminated
herpes zoster, Pneumocystis jiroveci pneumonia, cryptococ-
cosis, toxoplasmosis and should be watched out for [8, 17,
18].4 Pathology Research International
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Figure 5: Chest X-ray showing diﬀuse mottling of both lungs
simulating military tuberculosis.
6.LaboratoryDiagnosis
6.1. Cytological and Histological Examination. The diagnosis
of penicilliosis may be suspected or made through exami-
nation of cytology or biopsy specimens. Cytology specimens
are more readily obtained by less invasive procedures such as
ﬁne-needle aspiration of lymph nodes, sputum cytology and
touchsmearofskin[8,37,52–54].Forhighgradefungaemia,
yeast cells may be seen inside monocytes in peripheral blood
smear (Figure 6)[ 40]. The yeast cells may be sparse or
abundantly found in histiocytes or extracellularly (Figures 7
and 8), and are most readily demonstrated by fungal stains
such as periodic acid-Schiﬀ and silver methenamine stains
(Figure 9). Detection of nonbudding yeast cells with charac-
teristic central transverse septum would give a presumptive
diagnosis which should be conﬁrmed by microbiological
culture.
P. marneﬀei infection can sometimes be histologically
occult, and the yeast cells may resemble cellular debris
becauseoftheirsizeandstainingpattern.Furthermore,gran-
uloma formation may be absent because of anergic response
in AIDS. Therefore, fungal stains such as silver methenamine
stain should be performed on trephine biopsies in febrile
AIDS patients from endemic area even in the absence of
marrow granuloma [40].
A number of microorganisms have to be diﬀerentiated
from P. marneﬀei on cytologic preparation or tissue sec-
tion. Their distinguishing features are shown in Table 2.
Histoplasma capsulatum is the commonest microorganism
that may be confused with P. marneﬀei due to their similar
size and staining properties. Distinction between them relies
on the detection of central transverse septum which is
characteristic of P. marneﬀei as it reproduced by binary
ﬁssion or the demonstration of budding yeast cells which
Figure 6: Peripheral blood monocytes with ingested yeast cells
(May Gr¨ unwald Giemsa ×1000).
Figure 7: Lymph node biopsy showing histiocytic proliferation
withnumerousroundtooblongyeastcells(haematoxylinandeosin
×400).
are typical of Histoplasma species. Epidemiologic link to area
of endemicity of the two fungi can also aid in the diagnosis
[40, 52, 53, 55].
6.2.MicrobiologicalCulture. IsolationofP. marneﬀeiremains
the gold standard for diagnosis. Among all the clinical
specimens studied, the bone marrow gives the highest
yield for culture, approaching 100%. This is followed by
skin biopsy (90%) and blood culture (76%) [8]. HIV-
positive patients with penicilliosis have a higher incidence of
fungaemia when compared with HIV-negative patients [58,
59]. Both automated blood culture system and blood culture
medium for mycobacterium tuberculosis are able to support
the growth of P. marneﬀei [60]. The time to positivity for
automatedbloodcultureisaround4days(range:1.5–7days)
(personal observation). Although P. marneﬀei exists in yeast
form at 37◦C, septated hyphae-like structures but not yeast
cells are detected in the initial gram smear taken from thePathology Research International 5
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(b)
Figure 8: (a) Marrow aspirate showing a histiocyte engorged with
yeast cells with reddish pink inclusions (May Gr¨ unwald Giemsa
×1000). (b) Trephine biopsy showing histiocytic proliferation with
vague granuloma formation and ingested yeast cells. Some yeast
cells have transverse septum (arrow) (haematoxylin and eosin
×400).
positive blood culture (Figure 10) .T h eh y p h a es t r u c t u r e s
will break down into arthroconidia-like yeast cells with time.
6.3. Serology and Antigen Testing. Various types of antigen
and antibody testing speciﬁc to P. marneﬀei have been
described but they are not widely available [58, 61–67]. It
is noted that HIV-positive patients with penicilliosis have
a lower level of antibody and a higher level of antigen of
P. marneﬀei when compared with HIV-negative patients
penicilliosis [58]. Galactomannan assays for Aspergillus
species is also known to detect the galactomannan of Peni-
cillium species and can aid in the diagnosis of penicilliosis.
Among 15 cases of penicilliosis in HIV patient, 73.3%
was found to be positive with Platelia Aspergillus enzyme
immunoassaykit(Bio-rad)withamedianODindexof4.419
[68]. In another series, almost 80% of penicilliosis patient
was also found to be galactomannan positive by Pastorex
Aspergillus testing (Bio-rad) with a median titre of 1:8 [18].
Figure 9: Silver methenamine stain showing colonies of P. marn-
eﬀei.S o m ey e a s tc e l l sa r eo v a lt oo b l o n gi ns h a p ew i t hat r a n s v e r s e
septum (silver methenamine ×1000).
Figure 10: Septated hyphae-like structures but not yeast forms are
demonstrated in the initial gram smear taken from a positive blood
culture (Gram ×1000).
It is now our routine practice to screen all newly diagnosed
HIV-patients with galactomannan testing for early detection
of potential cases of penicilliosis.
6.4. Molecular Testing. PCR assayspeciﬁc forP. marneﬀeihas
been developed in research setting but is not available for
routine clinical use [69–73].
7. Treatment
7.1. Antifungal Susceptibility. There is no standardized tech-
nique or interpretation criteria for antifungal susceptibility
testing for dimorphic fungus. The result of susceptibility
testing in dimorphic fungus is inﬂuenced by the method,
incubation duration, incubation condition and medium
used. The inhibitory level of the same drug can be diﬀerent
against the yeast or the mycelial form of the same fungal
isolateandthecorrelationbetween invitrotesting andinvivo
eﬃcacy is largely unknown [74–76].6 Pathology Research International
Table 2: Distinguishing features of microorganisms which may be
confused with Penicillium marneﬀei in tissue examination [40, 56,
57].
Similarities Diﬀerences
Histoplasma
capsulatum
Yeast cells with similar
staining properties and
size
Found within histiocytes
and similar
inﬂammatory response
Budding instead of
septated yeast cells
Pneumocystis
jiroveci
Cyst form similar size
stained positive silver
methenamine stain
Round cysts containing
single or paired comma
shaped argyrophilic foci
in walls
Leishmania
spp.
Amastigotes within
histiocytes in H&E
section
Presence of bar shaped
kinetoplasts within
amastigotes seen under
oil immersion, PAS stain
negative
Toxoplasma
gondii
May appear as
intracellular organisms
in H&E section or
Giemsa stain
Size smaller, can be
found within in other
somatic cell types, not
stained with silver
methenamine
H&E: haematoxylin and eosin; PAS: periodic acid-Schiﬀ.
P. marneﬀei is susceptible to 5-ﬂucytosine and the azole
group of antifungal agents including miconazole, ketocona-
zole and itraconazole. Fluconazole is the least active among
the azoles in in vitro setting. Treatment response of the azoles
appears to correlate well with in vitro result, being high with
itraconazole but poor with ﬂuconazole. Amphotericin B is
clinically eﬀective although in vitro susceptibility test often
shows variable results [4, 74, 77].
For the newer antifungal agents, voriconazole has been
shown to have activity comparable with that of itraconazole
and the preliminary clinical data is encouraging [78, 79].
For the echinocandins, both anidulafungin and micafungin
have some degree of activity against P. marneﬀei [76,
80]. In in vitro testing, micafungin was found to have
synergistic eﬀect with itraconazole and to a lesser degree
with amphotericin B against P. marneﬀei [81]. However, it
is still uncertain whether this can be translated to clinical
management of human infection.
7.2. Antifungal Treatment. The mortality rate of untreated
penicilliosis is 100% [77]. Any delay in the initiation of
antifungal therapy is associated with poor outcome whereas
the therapeutic response is good with early institution of
treatment [8, 52, 77]. The recommended initial treatment
for penicilliosis in HIV-positive patients is intravenous
amphotericin B (0.6mg/kg) for 2 weeks followed by oral
itraconazole 400mg per day for 10 weeks [82]. Treatment
with itraconazole alone has also been shown to be eﬀective
but is associated with higher relapse rate [83]. It has been
recommended that itraconazole alone 400mg/day for 8
weeks could be considered for mild disease, followed by
maintenance therapy with 200 mg per day to prevent relapse
[82]. Oral itraconazole is available in capsule and solution
form. Oral absorption of capsule is dependent on a low
gastric pH and is enhanced by food or cola beverage [84, 85].
It can be erratically absorbed in patients with AIDS patients
who may have a low gastric pH and therefore serum levels
should be performed if available [86]. On the other hand,
itraconazole solution had a more reliable absorption with an
enhanced bioavailability but has to be taken on an empty
stomach [87, 88].
Two other important issues on the clinical management
of penicilliosis in HIV-positive patients require special
attention. The ﬁrst is drug interaction between antifungal
and antiretroviral agents. A lot of antiretrovirals are known
to interact with itraconazole. Itraconazole is a substrate of
CYP3A4 but can also inhibit metabolism of many CYP3A4
substrates and increased their concentration. It is known
to interact with protease inhibitors, and may increase the
plasma concentration of indinavir, ritonavir and saquinavir.
On the other hand, indinavir and ritonavir may also increase
the plasma concentration of itraconazole [89]. Nonnu-
cleoside reverse transcriptase inhibitors (NNRTIs) signiﬁ-
cantly reduce itraconazole concentration by promoting its
metabolism [90]. Maraviroc, a CCR5 antagonist, is metab-
olized by CYP3A4 and therefore itraconazole may increase
its concentration [91]. Most nucleoside reverse transcriptase
inhibitors (NRTIs) and raltegravir, an integrase inhibitor,
do not have signiﬁcant interactions with itraconazole. It is
important to check for drug interaction before starting the
antifungal or antiretroviral agents.
The second issue is the optimal timing of initiation of
HAART and the risk of development of immune restoration
inﬂammatory syndrome (IRIS) after HAART. Penicilliosis is
considered an AIDS-deﬁning illness in endemic areas [8–
10] and its diagnosis warrants initiation of HAART [92].
IRIS has only been uncommonly reported in patients with
penicilliosis and usually occurred a month after the start of
HAART [93–95]. Simultaneous initiation of HAART with
antifungal or delayed initiation until the end of the 2 weeks
of induction therapy of antifungal therapy can be considered
[82]. HAART should not be withheld because of concern for
possible development of IRIS. In case of severe symptomatic
IRIS, a short-course of steroids may be considered [82].
8. Prevention
During the pre-HAART era, over half of patients developed
relapse of penicilliosis within 6 months after discontinuation
of antifungal treatment [83, 96]. Secondary prophylaxis with
itraconazole 200mg/day was shown to be well tolerated
and highly eﬀective with a reduction in relapse rate from
57% to 0% [96]. Therefore, it has been recommended that
all patients who have completed treatment for penicilliosis
should be put on secondary prophylaxis with itraconazole
200mg/day [82].
With the introduction of HAART, there is growing data
to suggest that secondary prophylaxis can be stopped after
immune restoration [97, 98]. It is suggested that secondaryPathology Research International 7
prophylaxis can be stopped for patients who are receiving
HAART and have a CD4 count >100/uL for over 6 months.
However, secondary prophylaxis should be reintroduced if
the penicilliosis relapses or the CD4 count falls below 100/uL
[82].
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